Japanese pharmaceutical firm PeptiDream and France-based Ipsen have expanded their research collaboration and license option agreement signed in April 2013 to develop peptide drugs to treat serious endocrinologic disease.
The deal has now been extended to discover, assess, potentially develop and launch therapeutic peptides to treat serious medical conditions in areas of therapeutic focus for Ipsen.
The current collaboration combines PeptiDream's proprietary Peptide Discovery Platform System (PDPS) with Ipsen's expertise in peptide drug discovery and pharmaceutical R&D.
As part of the new deal, the collaboration will now be extended to allow further therapeutic peptide candidates to enter R&D for more serious endocrinologic disease.
Financial details of the expanded deal are not disclosed but are based on those of the existing collaboration.
The deal will see Ipsen will pay all R&D and commercialization costs in exchange for worldwide rights to each therapeutic peptide resulting from the deal.
Under the expanded deal, PeptiDream will receive royalties on worldwide sales or have the right to opt-in at predefined stages to support Japan development costs of each new candidate for royalty free commercial rights in that territory.
PeptiDream chief scientific officer and head of discovery programs Patrick Reid said, "This expanded partnership with Ipsen to discover novel therapeutic peptides for serious disease reinforces the positive collaborative relationship with Ipsen and further underlines the status of PeptiDream as a major force in therapeutic peptide discovery in the pharmaceutical industry worldwide."
